Comparative Pharmacology
Head-to-head clinical analysis: TIMENTIN versus TINDAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMENTIN versus TINDAMAX.
TIMENTIN vs TINDAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Timentin is a combination of ticarcillin, a penicillin-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and clavulanic acid, a beta-lactamase inhibitor that irreversibly inhibits a wide range of beta-lactamase enzymes, thereby preventing degradation of ticarcillin and extending its spectrum to include beta-lactamase-producing organisms.
Tindamax (tinidazole) is a nitroimidazole antibiotic that enters bacterial and protozoal cells, where the nitro group is reduced by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It exhibits activity against anaerobic bacteria and protozoa.
3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours; for moderate infections, 3.1 g IV every 6 hours; for severe infections, 3.1 g IV every 4 hours.
100 mg intravenously every 8 hours over 60 minutes.
None Documented
None Documented
Ticarcillin: ~1.1 hours; clavulanate: ~1.0 hours. Prolonged in renal impairment (CrCl <10 mL/min: ticarcillin half-life ~13 hours).
Terminal elimination half-life is 4-6 hours; prolonged to 10-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 60-80% ticarcillin and 50-70% clavulanate excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal: minimal.
Primarily renal excretion (70-80% as unchanged drug) with 10-15% fecal elimination via biliary secretion.
Category C
Category C
Antibiotic
Antibiotic